Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) – Pipeline Review, H1 2018’, provides in depth analysis on Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders and Oncology under development targeting Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

– The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects

– The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

3SBio Inc

Boehringer Ingelheim GmbH

Clementia Pharmaceuticals Inc

Galderma SA

Lee's Pharmaceutical Holdings Ltd

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

Valeant Pharmaceuticals International Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Overview

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Companies Involved in Therapeutics Development

3SBio Inc

Boehringer Ingelheim GmbH

Clementia Pharmaceuticals Inc

Galderma SA

Lee's Pharmaceutical Holdings Ltd

Phosphagenics Ltd

Promius Pharma LLC

Sol-Gel Technologies Ltd

Valeant Pharmaceuticals International Inc

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Drug Profiles

(adapalene + benzoyl peroxide + clindamycin phosphate) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(adapalene + clindamycin hydrochloride) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(benzoyl peroxide + tretinoin) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(clindamycin phosphate + tretinoin) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alitretinoin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bexarotene + CD1530 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palovarotene Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize RARG for Fibrosis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tazarotene Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPX-6001 + tretinoin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tretinoin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trifarotene Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Dormant Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Discontinued Products

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) Product Development Milestones

Featured News & Press Releases

Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

Nov 20, 2017: Preclinical study demonstrates promising treatment for rare bone disease

Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September

Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris

Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children’s Bone Health

Mar 28, 2017: Phase 2 Part A Open Label Extension Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva Continues Positive Trends

Nov 18, 2016: Clementia Clinical Program: Necker Begins Enrolling Patients in Palovarotene 2B Extension Study

Nov 18, 2016: Clementia Clinical Program: Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI) Begins Enrolling Patients in Palovarotene 2B Extension Study

Nov 14, 2016: Clementia Clinical Program: Clinical Trial Site for Palovarotene Study Opened in Argentina

Oct 14, 2016: Clementia Announces Top-line Results from Phase 2 Trial of Palovarotene for Treatment of Patients with Fibrodysplasia Ossificans Progressiva

Aug 08, 2016: Clementia Clinical Program: Opportunity for New Adult and Older Adolescent Subjects to Enroll in Palovarotene Study

Jun 13, 2016: Clementia Clinical Program: Next Step in Clementia’s Clinical Program for Fibrodysplasia Ossificans Progressiva (FOP)

Jun 09, 2016: Galderma Trifarotene Development Program Meets Key Milestone for Lamellar Ichthyosis Orphan Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by 3SBio Inc, H1 2018

Pipeline by Boehringer Ingelheim GmbH, H1 2018

Pipeline by Clementia Pharmaceuticals Inc, H1 2018

Pipeline by Galderma SA, H1 2018

Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2018

Pipeline by Phosphagenics Ltd, H1 2018

Pipeline by Promius Pharma LLC, H1 2018

Pipeline by Sol-Gel Technologies Ltd, H1 2018

Pipeline by Valeant Pharmaceuticals International Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports